Medical device company CryoLife Inc. CRY recently announced plans to settle the ongoing PerClot patent dispute with Medafor Inc., a subsidiary of C.R. Bard BCR. However, the settlement is subject to ...

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that the US Food and Drug Administration (FDA) granted premarket application (PMA) approval of ...

Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA, ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S.

Company said, "During the quarter we made significant progress in advancing our new product initiatives, enhancing our long-term growth potential. We received FDA approval to begin our pivotal ...

CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the enrollment of the first patient in its PerClot ...

Artivion Inc. (formerly Cryolife Inc.) received U.S. FDA premarket application (PMA) approval of its Perclot absorbable hemostatic system and promptly sold the product line to Baxter International Inc ...

Marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive solutions Indications: PerClot ...

ATLANTA, May 23, 2023 /PRNewswire/ --Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration ...